Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | CD274 pos KEAP1 mut |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
CD274 pos KEAP1 mut | lung non-small cell carcinoma | not predictive | Pembrolizumab | Clinical Study | Actionable | In a retrospective analysis of a Phase III trial (KEYNOTE-042), Keytruda (pembrolizumab) treatment resulted in a similar improved overall survival compared to chemotherapy in patients with CD274 (PD-L1)-positive non-small cell lung cancer with either a KEAP1 mutation (HR=0.75) or wild-type KEAP1 (HR=0.78) (PMID: 36709038; NCT02220894). | 36709038 |